2.2092
price down icon0.67%   -0.0308
 
loading
전일 마감가:
$2.24
열려 있는:
$2.23
하루 거래량:
726.50K
Relative Volume:
0.23
시가총액:
$58.49M
수익:
$155.00K
순이익/손실:
$-30.01M
주가수익비율:
-1.3229
EPS:
-1.67
순현금흐름:
$-11.98M
1주 성능:
-7.29%
1개월 성능:
-17.90%
6개월 성능:
-71.47%
1년 성능:
-68.44%
1일 변동 폭
Value
$2.1925
$2.30
1주일 범위
Value
$2.21
$2.44
52주 변동 폭
Value
$1.89
$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name
명칭
Inmune Bio Inc
Name
전화
(858) 964-3720
Name
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Name
직원
13
Name
트위터
@INmuneBio
Name
다음 수익 날짜
2025-08-01
Name
최신 SEC 제출 서류
Name
INMB's Discussions on Twitter

INMB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INMB
Inmune Bio Inc
2.20 67.26M 155.00K -30.01M -11.98M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
387.80 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.37 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.22 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
704.47 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
307.35 37.96B 3.81B -644.79M -669.77M -6.24

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-01 다운그레이드 BTIG Research Buy → Neutral
2025-07-01 다운그레이드 Scotiabank Sector Outperform → Sector Underperform
2025-01-28 개시 Rodman & Renshaw Buy
2024-10-21 개시 Alliance Global Partners Buy
2024-09-27 개시 Raymond James Outperform
2024-08-22 개시 Scotiabank Sector Outperform
2023-06-01 개시 Robert W. Baird Outperform
2022-05-24 다운그레이드 B. Riley Securities Buy → Neutral
2021-07-07 재확인 Maxim Group Buy
2021-04-21 개시 B. Riley Securities Buy
2021-01-22 재확인 Maxim Group Buy
2020-09-01 개시 BTIG Research Buy
2020-07-15 재확인 H.C. Wainwright Buy
모두보기

Inmune Bio Inc 주식(INMB)의 최신 뉴스

pulisher
Aug 16, 2025

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes - ADVFN Brasil

Aug 16, 2025
pulisher
Aug 14, 2025

Intraday Charts Show Spike in INmune Bio Inc. ActivityJuly 2025 Setups & Free Safe Capital Growth Stock Tips - beatles.ru

Aug 14, 2025
pulisher
Aug 13, 2025

Can Traders Expect Breakout From INmune Bio Inc. This WeekWeekly Trading Summary & AI Powered Buy/Sell Recommendations - 선데이타임즈

Aug 13, 2025
pulisher
Aug 13, 2025

Inmune Bio Inc. shares fall 1.24% premarket after Climb Bio reports financial results and Generation Bio announces new data. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

INmune Bio Inc. Recovery Potential Based on Technical ToolsChart-Based Trade Entries Gain Analyst Support - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

Undervalued Innovators in Biotech: Assessing Altimmune and INmune Bio's High-Risk, High-Reward Potential - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Inmune Bio’s Earnings Call: Progress Amid Challenges - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Inmune Bio Inc. shares fall 2.71% intraday as Climb Bio reports financial results and trial updates. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Inmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025
pulisher
Aug 10, 2025

INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift - MSN

Aug 10, 2025
pulisher
Aug 10, 2025

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Aug 10, 2025
pulisher
Aug 09, 2025

INmune Bio CEO Change and Strategic Shift: Core Therapeutic Areas Focus with Potential 199% Price Upside - AInvest

Aug 09, 2025
pulisher
Aug 08, 2025

INmune Bio Sets Mid-2026 Timeline for BLA and MAA Filings Amid CEO Transition - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: INmune Bio Q2 2025 reveals wider losses, stock tumbles - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: INmune Bio Q2 2025 reveals wider losses, stock tumbles By Investing.com - Investing.com South Africa

Aug 08, 2025
pulisher
Aug 08, 2025

Inmune Bio Inc. shares fall 14.69% premarket after missing primary cognitive endpoints in MINDFuL phase 2 trial. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio August 2025 slides: three-platform strategy shows clinical progress - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 08, 2025

Why Did INmune Bio Plunge 17.56%? Q2 Loss Widens 110% - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Transcript : INmune Bio, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio Reports Q2 2025 Net Loss of $24.5 Million, Announces CEO Retirement and $19 Million Registered Direct Offering - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio (INMB) Q2 Loss Widens 110% - AOL.com

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio Inc (INMB) Q2 2025 Earnings Call Highlights: Promisin - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio Reports Q2 2025 Results and Strategic Updates - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

INmune Bio Q2 Loss Worsens Amid Alzheimer's Trial Disappointment, Cash Reserves Increase - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio Completes Phase I/II Trial for INKmune™ - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio Inc Reports Q2 EPS of -$0.45, Missing Estimates; Reve - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio: Navigating the Crossroads of Clinical Promise and Financial Realities - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial - Investing.com Nigeria

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial By Investing.com - Investing.com South Africa

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio Announces Q2 2025 Results, Business Update, and Management Changes - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

INmune Bio's INKmune Hits End Points in mCR Prostate Cancer Trial - CGTLive®

Aug 07, 2025
pulisher
Aug 06, 2025

Inmune Bio Inc. shares fall 1.09% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Inmune Bio Q2 Earnings Preview: Consensus EPS Estimate at -$0.38 - AInvest

Aug 06, 2025
pulisher
Aug 05, 2025

INmune Bio Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Inmune Bio shares fall 4.73% premarket despite positive trial results for INKmune™ in prostate cancer. - AInvest

Aug 05, 2025
pulisher
Aug 04, 2025

INmune Bio stock holds steady as Raymond James reiterates Market Perform - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio’s Promising Phase 2 MINDFuL Trial Results Set to Stir Alzheimer’s Market​ - StocksToTrade

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio rises as prostate cancer therapy meets trial goals - TradingView

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio’s Future: Buying, Holding, or Selling? - timothysykes.com

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio stock up as prostate cancer trial succeeds (INMB) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

Volume Profile Shows Strong Base for INmune Bio Inc.Target Return Focused Trade Insights Shared - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio Stock Soars 25.78% on Pipeline Advancements - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio stock soars after prostate cancer trial meets endpoints By Investing.com - Investing.com Australia

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio stock soars after prostate cancer trial meets endpoints - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan

Aug 04, 2025
pulisher
Aug 03, 2025

When is INmune Bio Inc. stock expected to show significant growthFree Bull & Bear Market Updates - Jammu Links News

Aug 03, 2025

Inmune Bio Inc (INMB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Inmune Bio Inc 주식 (INMB) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Tesi Raymond Joseph
President and CEO
Sep 12 '24
Buy
6.38
15,380
98,048
1,554,106
Moss David J
Chief Financial Officer
Sep 12 '24
Buy
6.38
7,690
49,024
1,275,869
$24.46
price up icon 0.68%
$83.82
price down icon 1.10%
$26.89
price up icon 2.17%
$103.94
price down icon 1.02%
$131.26
price up icon 2.26%
biotechnology ONC
$307.37
price down icon 0.42%
자본화:     |  볼륨(24시간):